DNY59/E+ by way of Getty Pictures
Hedge funds specializing in biotech lastly caught a break this summer season, courtesy of a little-watched French drug developer, The Wall Avenue Journal reported on Saturday.
Paris-based Abivax (NASDAQ:ABVX) (OTCPK:AAVXF), which had been valued at roughly $500 million earlier
